Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | HBB | P68871 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL141410 | 0.97 | ALDH1A1 (0.52) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL29112128 | 0.87 | ALDH1A1 (0.48) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL12476115 | 0.84 | ALDH1A1 (0.74) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL28848588 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL16347818 | 0.80 | PI4KA (0.41) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11135477 | 0.72 | TDP1 (0.44) | ALDH1A1LRRK2XDHTDP1TP53 | |
| Thioguanine SCHEMBL3701 | 0.72 | PNP (0.62) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL1176577 | 0.72 | PNP (0.62) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL28385604 | 0.71 | PNP (0.61) | ALDH1A1PI4KAPI4K2BPI4K2API4KB | |
| Hypoxanthine SCHEMBL25381 | 0.70 | ALDH1A1 (1.00) | ALDH1A1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 121205 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-4790948-A | MODIFYING ADDITION COPOLYMER OF UNSATURATED EPOXIDES WITH POLYAMINE AND SULFUR-NITROGEN HETEROCYCLIC COMPOUND | TEXACO INC. (US) | 1988-12-13 | — | — | US | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |
| EP-0073490-B1 | DIHYDROTHIAZOLE-PURINES | Newport Pharmaceuticals International, Inc. (US) | 1986-04-30 | — | — | EP | claimed |
| EP-0081882-B1 | MEDICINE HAVING TRANSPLANT REJECTION AND/OR IMMUNOLOGICAL INFLAMMATION INHIBITING ACTIVITIES, AS WELL AS A METHOD FOR INHIBITING TRANSPLANT REJECTION AND/OR IMMUNOLOGICAL INFLAMMATION | Erasmus Universiteit Rotterdam (NL) | 1986-04-16 | — | — | EP | claimed |
| EP-0169618-A2 | Method for making uniformly sized particles from water-insoluble organic compounds | STERILIZATION TECHNICAL SERVICES, Inc. (US) | 1986-01-29 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| US-4452794-A | MIXTURE OF A PROSTAGLANDIN DERIVATIVE AND A CORTICOSTEROID OR A MERCAPTOPURINE | ERASMUS UNIVERSITEIT ROTTERDAM (NL) | 1984-06-05 | — | — | US | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0081882-A1 | Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation | Erasmus Universiteit Rotterdam (NL) | 1983-06-22 | — | — | EP | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |